These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 36594261)

  • 1. Cross-neutralization and viral fitness of SARS-CoV-2 Omicron sublineages.
    Xia H; Yeung J; Kalveram B; Bills CJ; Chen JY; Kurhade C; Zou J; Widen SG; Mann BR; Kondor R; Davis CT; Zhou B; Wentworth DE; Xie X; Shi PY
    Emerg Microbes Infect; 2023 Dec; 12(1):e2161422. PubMed ID: 36594261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutralization of Omicron sublineages and Deltacron SARS-CoV-2 by three doses of BNT162b2 vaccine or BA.1 infection.
    Kurhade C; Zou J; Xia H; Liu M; Yang Q; Cutler M; Cooper D; Muik A; Sahin U; Jansen KU; Ren P; Xie X; Swanson KA; Shi PY
    Emerg Microbes Infect; 2022 Dec; 11(1):1828-1832. PubMed ID: 35792746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The viral fitness and intrinsic pathogenicity of dominant SARS-CoV-2 Omicron sublineages BA.1, BA.2, and BA.5.
    Shuai H; Chan JF; Hu B; Chai Y; Yoon C; Liu H; Liu Y; Shi J; Zhu T; Hu JC; Hu YF; Hou Y; Huang X; Yuen TT; Wang Y; Zhang J; Xia Y; Chen LL; Cai JP; Zhang AJ; Yuan S; Zhou J; Zhang BZ; Huang JD; Yuen KY; To KK; Chu H
    EBioMedicine; 2023 Sep; 95():104753. PubMed ID: 37579626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cross-neutralization of Omicron BA.1 against BA.2 and BA.3 SARS-CoV-2.
    Zou J; Kurhade C; Xia H; Liu M; Xie X; Ren P; Shi PY
    Nat Commun; 2022 May; 13(1):2956. PubMed ID: 35618703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SARS-CoV-2 Omicron sublineages exhibit distinct antibody escape patterns.
    Gruell H; Vanshylla K; Korenkov M; Tober-Lau P; Zehner M; Münn F; Janicki H; Augustin M; Schommers P; Sander LE; Kurth F; Kreer C; Klein F
    Cell Host Microbe; 2022 Sep; 30(9):1231-1241.e6. PubMed ID: 35921836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significant neutralizing escapes of Omicron and its sublineages in SARS-CoV-2-infected individuals vaccinated with inactivated vaccines.
    Shen F; Yang CX; Lu Y; Zhang M; Tian RR; Dong XQ; Li AQ; Zheng YT; Pang W
    J Med Virol; 2023 Feb; 95(2):e28516. PubMed ID: 36680413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exposure to BA.4/5 S protein drives neutralization of Omicron BA.1, BA.2, BA.2.12.1, and BA.4/5 in vaccine-experienced humans and mice.
    Muik A; Lui BG; Bacher M; Wallisch AK; Toker A; Couto CIC; Güler A; Mampilli V; Schmitt GJ; Mottl J; Ziegenhals T; Fesser S; Reinholz J; Wernig F; Schraut KG; Hefesha H; Cai H; Yang Q; Walzer KC; Grosser J; Strauss S; Finlayson A; Krüger K; Ozhelvaci O; Grikscheit K; Kohmer N; Ciesek S; Swanson KA; Vogel AB; Türeci Ö; Sahin U
    Sci Immunol; 2022 Dec; 7(78):eade9888. PubMed ID: 36378074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A fourth dose of Omicron RBD vaccine enhances broad neutralization against SARS-CoV-2 variants including BA.1 and BA.2 in vaccinated mice.
    Zhou B; Song S; Guo H; Zhou X; Fan Q; Liu W; Cheng L; Ge X; Ju B; Zhang Z
    J Med Virol; 2022 Aug; 94(8):3992-3997. PubMed ID: 35474319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Omicron BA.1 breakthrough infections in inactivated COVID-19 vaccine recipients induced distinct pattern of antibody and T cell responses to different Omicron sublineages.
    Guo L; Zhang Q; Zhong J; Chen L; Jiang W; Huang T; Li Y; Zhang Y; Xu L; Wang X; Xiao Y; Wang Y; Dong X; Dong T; Peng Y; Zhang B; Xie Y; Gao H; Shen Z; Ren L; Cheng T; Wang J
    Emerg Microbes Infect; 2023 Dec; 12(1):2202263. PubMed ID: 37037791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antigenic cartography of well-characterized human sera shows SARS-CoV-2 neutralization differences based on infection and vaccination history.
    Wang W; Lusvarghi S; Subramanian R; Epsi NJ; Wang R; Goguet E; Fries AC; Echegaray F; Vassell R; Coggins SA; Richard SA; Lindholm DA; Mende K; Ewers EC; Larson DT; Colombo RE; Colombo CJ; Joseph JO; Rozman JS; Smith A; Lalani T; Berjohn CM; Maves RC; Jones MU; Mody R; Huprikar N; Livezey J; Saunders D; Hollis-Perry M; Wang G; Ganesan A; Simons MP; Broder CC; Tribble DR; Laing ED; Agan BK; Burgess TH; Mitre E; Pollett SD; Katzelnick LC; Weiss CD
    Cell Host Microbe; 2022 Dec; 30(12):1745-1758.e7. PubMed ID: 36356586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SARS-CoV-2 Omicron sublineages show comparable cell entry but differential neutralization by therapeutic antibodies.
    Arora P; Zhang L; Krüger N; Rocha C; Sidarovich A; Schulz S; Kempf A; Graichen L; Moldenhauer AS; Cossmann A; Dopfer-Jablonka A; Behrens GMN; Jäck HM; Pöhlmann S; Hoffmann M
    Cell Host Microbe; 2022 Aug; 30(8):1103-1111.e6. PubMed ID: 35588741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody affinity and cross-variant neutralization of SARS-CoV-2 Omicron BA.1, BA.2 and BA.3 following third mRNA vaccination.
    Bellusci L; Grubbs G; Zahra FT; Forgacs D; Golding H; Ross TM; Khurana S
    Nat Commun; 2022 Aug; 13(1):4617. PubMed ID: 35941152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Omicron BA.2 breakthrough infection enhances cross-neutralization of BA.2.12.1 and BA.4/BA.5.
    Muik A; Lui BG; Bacher M; Wallisch AK; Toker A; Finlayson A; Krüger K; Ozhelvaci O; Grikscheit K; Hoehl S; Ciesek S; Türeci Ö; Sahin U
    Sci Immunol; 2022 Nov; 7(77):eade2283. PubMed ID: 36125366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine.
    Kurhade C; Zou J; Xia H; Cai H; Yang Q; Cutler M; Cooper D; Muik A; Jansen KU; Xie X; Swanson KA; Shi PY
    Nat Commun; 2022 Jun; 13(1):3602. PubMed ID: 35739094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antigenic Cartography Indicates That the Omicron BA.1 and BA.4/BA.5 Variants Remain Antigenically Distant to Ancestral SARS-CoV-2 after Sputnik V Vaccination Followed by Homologous (Sputnik V) or Heterologous (Comirnaty) Revaccination.
    Astakhova EA; Morozov AA; Byazrova MG; Sukhova MM; Mikhailov AA; Minnegalieva AR; Gorchakov AA; Filatov AV
    Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutralization of SARS-CoV-2 Omicron sublineages by 4 doses of the original mRNA vaccine.
    Xie X; Zou J; Kurhade C; Liu M; Ren P; Pei-Yong Shi
    Cell Rep; 2022 Nov; 41(9):111729. PubMed ID: 36402138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Heterologous Challenge Rescues the Attenuated Immunogenicity of SARS-CoV-2 Omicron BA.1 Variant in Syrian Hamster Model.
    Ma J; Liu X; Zhou M; Chen P; Chen R; Wang J; Zhu H; Wu K; Ye J; Zhang Y; Yuan Q; Tang Q; Yuan L; Cheng T; Guan Y; Xia N
    J Virol; 2023 Feb; 97(2):e0168422. PubMed ID: 36651747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progressive loss of conserved spike protein neutralizing antibody sites in Omicron sublineages is balanced by preserved T cell immunity.
    Muik A; Lui BG; Quandt J; Diao H; Fu Y; Bacher M; Gordon J; Toker A; Grosser J; Ozhelvaci O; Grikscheit K; Hoehl S; Kohmer N; Lustig Y; Regev-Yochay G; Ciesek S; Beguir K; Poran A; Vogler I; Türeci Ö; Sahin U
    Cell Rep; 2023 Aug; 42(8):112888. PubMed ID: 37527039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum neutralization of SARS-CoV-2 Omicron BA.2, BA.2.75, BA.2.76, BA.5, BF.7, BQ.1.1 and XBB.1.5 in individuals receiving Evusheld.
    Zhao Q; Wang X; Zhang Z; Liu X; Wang P; Cao J; Liang Q; Qu J; Zhou M
    J Med Virol; 2023 Jul; 95(7):e28932. PubMed ID: 37403923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A machine learning model for predicting serum neutralizing activity against Omicron SARS-CoV-2 BA.2 and BA.4/5 sublineages in the general population.
    Camacho J; Albert E; Álvarez-Rodríguez B; Rusu L; Zulaica J; Moreno AR; Peiró S; Geller R; Navarro D; Giménez E
    J Med Virol; 2023 Apr; 95(4):e28739. PubMed ID: 37185857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.